{"disease":{"id":"gastrooesophageal-cancer","name":"gastrooesophageal cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03416244","title":"A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT05071053","title":"Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT05965479","title":"Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"University of Southampton","has_results":false},{"nct_id":"NCT02884453","title":"Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":17,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT02274012","title":"Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Columbia University","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}